News
Credit: PowerUp/Shutterstock. Vivace Therapeutics has closed $35m in a Series D financing round to support the clinical development of its cancer drug VT3989. VT3989 is a transcriptional enhanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback